Mechanisms proposed for rituximab (direct binding of the antibody to its antigen, resulting in cytokine release) and cetuximab (formation of IgE antidrug antibody complexes leading to allergic reactions or anaphylaxis [16, 17]) are not thought to be implicated in IRRs to ramucirumab. The gene discussed is IGHE; the disease is anaphylaxis.